Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement

• Main Authors: Tae Jung Oh (Author), Ju-Young Moon (Author), Kyu Yeon Hur (Author), Seung Hyun Ko (Author), Hyun Jung Kim (Author), Taehee Kim (Author), Dong Won Lee (Author), Min Kyong Moon (Author), The Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology (Author)
• Format: Book
• Published: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome trials of sodiumglucose cotransporter-2 (SGLT2) inhibitors showed profound reno-protective effe...